UPSTREAM BIO, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
UPSTREAM BIO, INC. (UPB) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$223.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-11
- UPSTREAM BIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$223.00K.
- UPSTREAM BIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$430.00K, a 209.41% decline year-over-year.
- UPSTREAM BIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $37.00K.
- UPSTREAM BIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $235.00K, a 42.12% decline year-over-year.
- UPSTREAM BIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $555.00K.
- UPSTREAM BIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$46.00K, a 319.05% decline from fiscal 2023.
- UPSTREAM BIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $21.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$223.00K 10-Q · filed 2026-08-11 | -$653.00K 10-Q · filed 2026-08-11 | -$616.00K derived: sum of 3 quarters · filed 2026-08-11 | -$381.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$430.00K 10-Q · filed 2026-05-13 | -$393.00K derived: sum of 2 quarters · filed 2026-05-13 | -$158.00K derived: sum of 3 quarters · filed 2026-05-13 | -$268.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $37.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $272.00K derived: sum of 2 quarters · filed 2026-03-26 | $162.00K derived: sum of 3 quarters · filed 2026-08-11 | $555.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $235.00K 10-Q · filed 2025-11-05 | $125.00K derived: sum of 2 quarters · filed 2026-08-11 | $518.00K 10-Q · filed 2025-11-05 | $142.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$110.00K 10-Q · filed 2026-08-11 | $283.00K 10-Q · filed 2026-08-11 | -$93.00K derived: sum of 3 quarters · filed 2026-08-11 | $313.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $393.00K 10-Q · filed 2026-05-13 | $17.00K derived: sum of 2 quarters · filed 2026-05-13 | $423.00K derived: sum of 3 quarters · filed 2026-05-13 | $389.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$376.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $30.00K derived: sum of 2 quarters · filed 2026-03-26 | -$4.00K derived: sum of 3 quarters · filed 2026-03-26 | -$46.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $406.00K 10-Q · filed 2025-11-05 | $372.00K derived: sum of 2 quarters · filed 2025-11-05 | $330.00K 10-Q · filed 2025-11-05 | |
| 2024-06-30 | -$34.00K 10-Q · filed 2025-08-06 | -$76.00K 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | -$42.00K 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $21.00K 10-K · filed 2025-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |